ArticleInternational archives of allergy and immunology2025
α2-3 Sialic Acids-Decorated Allergens Exert a Tolerogenic Effect on CD4+ T Cells from Der p 2-Allergic Patients.
Article in International archives of allergy and immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAllergen-specific immunotherapy is so far the only disease-modifying therapy for allergy, resulting in a long-lasting tolerance. However, the existing safety concerns and the need for more efficacious alternatives that shorten the duration of treatment have stimulated research into the development of novel alternatives. Some of these novel alternatives involve modifying allergens with molecules that target innate immunomodulatory receptors to suppress the immune activity of immune cells.
methodsFreshly prepared monocyte-derived dendritic cells (moDCs) from mite-allergic and non-atopic volunteers were treated with α2-3 sialic acid-conjugated recombinant Der p 2 (sia-Der p 2) and unconjugated Der p 2 in culture and matured with toll-like receptor 1/2 (Pam3CSK4) (Pam3) and 2/4 (lipopolysaccharide [LPS]) agonists, followed by coculture with autologous CD4+ T cells. Secretion of cytokines in supernatants was measured by ELISA, and expression of cell surface and intracellular markers was measured by flow cytometry.
resultsSia-Der p 2 unlike Der p 2 modulated moDCs from mite-allergic volunteers by reducing expression of CD83 and CXCR5. We also observed that sia-Der p 2-treated moDCs in the presence of Pam3 and LPS significantly suppressed the proportion of CD25+, Ki67+, IL-13+, and IFNγ+ CD4+ T cells of mite-allergic volunteers, while Der p 2-treated moDCs did not. Sia-Der p 2-treated moDC did not alter these CD4+ T-cell populations in non-atopic volunteers.
conclusionOur data suggest that Der p 2 conjugated with α2-3 sialic acids modifies moDCs and promotes the differentiation of allergen-specific CD4+ T cells toward a regulatory profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.